Hyponatremia treatment guidelines 2007: expert panel recommendations.

Area of Science:

• Endocrinology and Nephrology
• Pharmacology
• Internal Medicine

Background:

• Hyponatremia is a prevalent electrolyte disorder with potential for severe morbidity and mortality, especially in complex cases.
• Rapid correction of chronic hyponatremia poses risks, including fatal neurologic deficits, with established optimal strategies lacking.
• Arginine vasopressin receptor (AVPR) antagonists are a class of drugs with aquaretic properties.

Purpose of the Study:

• To evaluate the potential role of nonpeptide small-molecule AVPR antagonists in hyponatremia management.
• To identify suitable patient populations for current and future therapies involving AVPR antagonists.
• To review expert conclusions on the therapeutic contributions of aquaretic AVPR antagonists.

Main Methods:

• Expert panel review and discussion.
• Assessment of existing literature and clinical data.
• Synthesis of conclusions regarding AVPR antagonist applications.

Main Results:

• Identification of specific patient cohorts who may benefit from AVPR antagonist therapy.
• Discussion of the mechanism of action of AVPR antagonists as aquaretics.
• Exploration of potential future indications beyond current treatment paradigms.

Conclusions:

• Aquaretic AVPR antagonists represent a potential therapeutic advancement for hyponatremia.
• Careful patient selection is crucial for effective and safe utilization of these agents.
• Further research may expand the application of AVPR antagonists in managing electrolyte imbalances.